Skip to main content

Table 4 Long-term Outcomes According to AIP index before and after Multivariate COX Regression Adjustment

From: Atherogenic index of plasma for non-diabetic, coronary artery disease patients after percutaneous coronary intervention: a prospective study of the long-term outcomes in China

Endpoints

No. of events (%)

Hazard ratio (95% confidence interval)

P value

Adjusted hazard ratio (95% confidence interval)

Adjusted P value

Primary endpoint

 MACE

  Tertile 1

88 (4.8)

Ref

Ref

Ref

Ref

  Tertile 2

85 (4.6)

0.96 (0.71–1.30)

0.801

0.93 (0.69–1.27)

0.656

  Tertile 3

120 (6.5)

1.37 (1.04–1.81)

0.025*

1.36 (1.01–1.82)

0.042*

Secondary endpoint

 Cardiac death/MI

  Tertile 1

20 (1.1)

Ref

Ref

Ref

Ref

  Tertile 2

21 (1.1)

1.03 (0.56–1.91)

0.919

1.10 (0.59–2.06)

0.766

  Tertile 3

36 (2.0)

1.81 (1.05–3.13)

0.033*

2.10 (1.17–3.78)

0.013*

 All-cause death

  Tertile 1

27 (1.5)

Ref

Ref

Ref

Ref

  Tertile 2

23 (1.2)

0.83 (0.48–1.46)

0.521

1.00 (0.55–1.80)

0.993

  Tertile 3

13 (0.7)

0.48 (0.25–0.93)

0.029*

0.60 (0.29–1.24)

0.169

 Cardiac death

  Tertile 1

14 (0.7)

Ref

Ref

Ref

Ref

  Tertile 2

9 (0.5)

0.61 (0.27–1.42)

0.256

0.88 (0.37–2.13)

0.777

  Tertile 3

9 (0.5)

0.64 (0.28–1.47)

0.289

1.10 (0.45–2.71)

0.828

 TVR

  Tertile 1

70 (3.8)

Ref

Ref

Ref

Ref

  Tertile 2

72 (3.9)

1.03 (0.74–1.43)

0.866

0.98 (0.70–1.37)

0.903

  Tertile 3

105 (5.7)

1.51 (1.11–2.03)

0.008*

1.40 (1.01–1.93)

0.042*

 Stroke

  Tertile 1

32 (1.7)

Ref

Ref

Ref

Ref

  Tertile 2

23 (1.2)

0.69 (0.40–1.18)

0.176

0.75 (0.42–1.33)

0.319

  Tertile 3

27 (1.5)

0.83 (0.50–1.39)

0.478

1.01 (0.58–1.75)

0.973

 Myocardial infarction

  Tertile 1

12 (0.7)

Ref

Ref

Ref

Ref

  Tertile 2

15 (0.8)

1.26 (0.59–2.67)

0.564

1.23 (0.57–2.66)

0.605

  Tertile 3

32 (1.7)

2.69 (1.38–5.22)

0.004*

2.82 (1.39–5.72)

0.004*

  1. Confounding factors for adjustment: common and possible confounding factors described in Table 3 were enrolled, including age, male, BMI, classification of CAD, hypertension, hyperlipidemia, renal dysfunction, smoker, cerebrovascular diseases, pre-PCI, pre-CABG, pre-myocardial infarction, COPD, peripheral vascular disease, CTO, TVD, creatine, albumin, left main involved, β-blocker at discharge, statin at discharge, ACEI/ARB at discharge, CCB at discharge
  2. MACE, major adverse cardiovascular events; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention
  3. *p < 0.05